United States Generic Drugs Market, By Type (Small Molecule Generics, Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Infectious Diseases, Others), By Mode of Drug Delivery (Oral, Topical, Parenteral, Others), By Form (Tablet, Capsule, Injection, Others), By Source (In House, Contract Manufacturing Organizations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 130.24 Billion
CAGR (2026-2031)	7.44%
Fastest Growing Segment	Oral
Largest Market	Mid-West
Market Size (2031)	USD 200.33 Billion

Market Overview

The United States Generic Drugs Market will grow from USD 130.24 Billion in 2025 to USD 200.33 Billion by 2031 at a 7.44% CAGR. Generic drugs are pharmaceutical products considered bioequivalent to their brand-name counterparts, featuring identical active ingredients, strength, dosage form, and route of administration, and are approved by the U.S. Food and Drug Administration following patent expiry. The market's growth is primarily driven by the consistent expiration of patents for blockbuster brand-name medications, alongside persistent pressure to contain healthcare costs by offering more affordable treatment options. Further impetus comes from supportive government policies that actively encourage generic drug prescribing and utilization. According to the Association for Accessible Medicines, in 2024, generic and biosimilar medicines comprised 90% of all prescriptions filled in the U.S., while accounting for only 12% of total prescription drug spending.

However, the U.S. generic drugs market faces a significant challenge in the form of substantial price erosion and high buyer concentration, particularly from pharmacy benefit managers. This environment contributes to declining profitability for generic manufacturers, potentially leading to market exits and exacerbating drug shortages.

Key Market Drivers

Patent Expirations as a Growth Catalyst for U.S. Generics
The continuous expiration of brand-name drug patents serves as a primary catalyst for growth within the United States Generic Drugs Market. As patents for high-revenue pharmaceuticals expire, generic manufacturers gain the opportunity to introduce more affordable bioequivalent versions, significantly expanding market access and competition. This mechanism is crucial for the generic sector's vitality, directly correlating the availability of new generic options with the volume of expiring proprietary drug protections. The U.S. market is projected to experience over $230 billion in lost revenue for branded drugs between 2025 and 2030 due to patent expirations, according to Drug Discovery News, February 2026, in "Blockbuster drugs face a massive patent cliff in 2026". This substantial shift creates significant opportunities for generic manufacturers.

Cost Containment and Savings Drive Generic Adoption
Furthermore, persistent demands for healthcare cost containment and increased affordability profoundly influence the generic drug market. Generic medications provide a cost-effective alternative to expensive brand-name drugs, which is critical for patients, insurers, and healthcare systems striving to manage expenditures. This economic advantage drives the adoption and utilization of generics across various therapeutic areas. According to the Association for Accessible Medicines, September 2025, in the "2025 U.S. Generic & Biosimilar Medicines Savings Report", generic and biosimilar medicines generated $467 billion in savings for patients and the U.S. healthcare system in 2024. Overall, the strategic importance of generic drugs in the U.S. healthcare landscape is underscored by their role in drug accessibility. According to the Association for Accessible Medicines, in 2024, 3.9 billion generic prescriptions were filled.

Download Free Sample Report

Key Market Challenges

Pricing pressure and buyer concentration impede growth
The United States generic drugs market faces significant headwinds from substantial price erosion and high buyer concentration, primarily driven by pharmacy benefit managers. This environment creates considerable pressure on generic manufacturers, directly undermining market growth. The aggressive pricing strategies employed by powerful buyers result in declining profitability for manufacturers, reducing the financial incentive to invest in research, development, and the sustained production of vital generic medications.

Sales decline and consolidation threaten market sustainability
According to the Association for Accessible Medicines, the overall value of generic sales in the U.S. has declined by $6.4 billion since 2019, despite increased utilization and new product launches. Such deflationary pressures render market participation increasingly unsustainable, particularly for smaller manufacturers, potentially leading to market exits. This consolidation of supply reduces competition and exacerbates drug shortages, thereby limiting the availability of affordable treatment options and ultimately constraining the market's expansion capacity.

Key Market Trends

Biosimilars Propel Diversification and Competition in the US Generic Market
The expansion into complex generics and biosimilars significantly diversifies the United States Generic Drugs Market, moving beyond traditional small-molecule products into intricate biological therapies. This trend is fueled by the considerable cost savings biosimilars offer for expensive biologic treatments for conditions like autoimmune disorders and cancer. As more blockbuster biologics lose patent protection, manufacturers are increasingly developing these advanced alternatives to capture a share of this high-value segment and enhance patient access. The United States Food and Drug Administration has now approved 86 biosimilars in total, with the most recent additions arriving in May 2026. This ongoing regulatory activity highlights the growing emphasis on fostering competition and affordability in the biologics sector.

Emphasis on Domestic Manufacturing and Supply-Chain Resilience for Generics
An increased focus on domestic manufacturing and supply chain resiliency is concurrently reshaping the U.S. generic drugs landscape. Global supply chain vulnerabilities have underscored the strategic imperative to reduce reliance on foreign active pharmaceutical ingredient and finished drug product manufacturing. This shift is backed by government initiatives and industry investments aimed at bolstering national drug security and ensuring a stable supply of essential medicines. Between February 1 and March 1, 2026, the FDA received over 80 requests to participate in the FDA PreCheck Pilot Program, an initiative designed to accelerate domestic drug manufacturing. This strong industry interest reflects a concerted effort to localize production and mitigate future supply shocks.

Segmental Insights

Oral Generics: Fastest Growth Fueled by Convenience, FDA Pathways, and Infrastructure.
The United States Generic Drugs Market identifies the Oral segment as the fastest growing due to several strategic advantages. Its rapid expansion stems from widespread patient preference for convenient, self-administered solid dosage forms, which significantly enhances medication adherence. Crucially, the U.S. Food and Drug Administration (FDA) provides a more streamlined and quicker approval pathway for generic oral solids compared to complex injectable or other formulations, accelerating market entry. Additionally, the well-established manufacturing infrastructure and consistent expiry of patents for numerous blockbuster oral drugs further fuel this segment's leading growth trajectory.

Regional Insights

Midwest Maintains Leadership in US Generic Drugs Market
The Mid-West is projected to maintain its leading position within the United States Generic Drugs Market. This regional dominance is attributed to several key factors, including a significant prevalence of chronic diseases and a substantial aging population, which together drive consistent demand for affordable medications. Furthermore, the Mid-West benefits from the established presence of major pharmaceutical companies and a robust healthcare infrastructure. Supportive government initiatives that actively promote the utilization of generic drugs further reinforce the region's prominent market standing.

Recent Developments

• In August 2025, Viatris Inc. received approval from the U.S. Food and Drug Administration for its iron sucrose injection, signaling an upcoming new product launch in the United States Generic Drugs Market. This approval represented the first generic version of the branded therapy Venofer, which is utilized for treating iron deficiency anemia in patients with chronic kidney disease. The introduction of this generic product in multiple dosage strengths was anticipated to enhance treatment accessibility and provide a cost-effective alternative for patients across the U.S.
• In February 2025, Sandoz launched Pyzchiva (ustekinumab-ttwe) in the United States, a significant new product entry as a biosimilar within the generic drugs market. This introduction represented an expansion of the company's leading biosimilar pipeline and offered a high-quality, more affordable treatment option for patients. The launch underscored Sandoz's strategic commitment to broadening access to essential medicines and capturing a share of the evolving biosimilar market in the U.S., contributing to overall healthcare savings.
• In June 2024, Teva Pharmaceuticals initiated the launch of the first generic version of liraglutide injection 1.8mg, referencing Victoza, within the United States market. This significant event marked the introduction of the first generic GLP-1 drug available for patients managing type 2 diabetes in the U.S. The company's action aimed to broaden patient access to essential treatments by providing a more cost-effective alternative. This introduction was a notable development in the United States Generic Drugs Market, directly contributing to increased competition and affordability for a widely used therapeutic class.
• In 2024, Amneal Pharmaceuticals significantly expanded its portfolio within the United States Generic Drugs Market by launching 22 new retail generic products. This initiative was part of the company's commitment to increasing access to affordable medications across America. Alongside these generic introductions, Amneal also strengthened its biosimilars pipeline, indicating a strategic focus on offering lower-cost alternatives for complex biologics. These launches contributed to an estimated $18.25 billion in patient savings during 2024, addressing critical needs and mitigating drug shortages for several essential injectable medicines in U.S. hospitals.

Key Market Players

• Teva Pharmaceuticals USA, Inc.
• Pfizer Inc.
• Sandoz US
• Endo International plc
• Aurobindo Pharma USA, Inc.
• Abbott Laboratories Inc.
• Eli Lilly and Company
• Sun Pharma USA
• Lupin Pharmaceuticals, Inc.
• Zydus Pharmaceuticals USA

By Type	By Application	By Mode of Drug Delivery	By Form	By Source	By Distribution Channel	By Region
Small Molecule Generics Biosimilars	Cardiovascular Diseases Diabetes Neurology Oncology Infectious Diseases Others	Oral Topical Parenteral Others	Tablet Capsule Injection Others	In House Contract Manufacturing Organizations	Hospital Pharmacies Retail Pharmacies Online Pharmacies Others	Northeast Midwest South West

Report Scope:

In this report, the United States Generic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Generic Drugs Market, By Type:

• Small Molecule Generics
• Biosimilars

• United States Generic Drugs Market, By Application:

• Cardiovascular Diseases
• Diabetes
• Neurology
• Oncology
• Infectious Diseases
• Others

• United States Generic Drugs Market, By Mode of Drug Delivery:

• Oral
• Topical
• Parenteral
• Others

• United States Generic Drugs Market, By Form:

• Tablet
• Capsule
• Injection
• Others

• United States Generic Drugs Market, By Source:

• In House
• Contract Manufacturing Organizations

• United States Generic Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

• United States Generic Drugs Market, By Region:

• Northeast
• Midwest
• South
• West